PolyPid Ltd. announced new Phase 3 SHIELD II trial data demonstrating that its product D-PLEX₁₀₀ provides sustained local release of the antibiotic doxycycline for about 30 days at surgical sites, significantly reducing surgical site infections (SSIs). The data showed continuous drug presence with minimal systemic exposure, addressing a key limitation of traditional antibiotics. D-PLEX₁₀₀ recently achieved a 60% reduction in SSIs in abdominal colorectal surgery and has FDA Breakthrough Therapy designation. The findings will be presented at ESCMID Global 2026, highlighting its potential to improve post-surgical infection prevention.
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
Bitcoin's price surged to nearly $65,000 following softer-than-expected U.S. inflation data for June, easing fears of Federal Reserve rate hikes. However, on-chain data reveals two main groups of investors—long-term holders who bought near last year'...
Bitcoin miners are experiencing declining revenue as the network's hash rate and mining difficulty fall, reflecting a shift of miners into AI infrastructure. Despite this stress, miners are accumulating Bitcoin, with reserves increasing by 1%, signal...
